Forest Labs Sues Sigmapharm To Halt Generic Antipsychotic

Law360, New York (September 4, 2014, 6:18 PM EDT) -- Forest Laboratories LLC sued Sigmapharm Laboratories LLC in Delaware federal court Wednesday over the generic-drug maker's plan to sell a version of Forest's schizophrenia and bipolar treatment drug Saphris.

The suit claims Sigmapharm infringed two patents related to the manufacture of Saphris when it filed an abbreviated new drug application with the U.S. Food and Drug Administration to market a generic version of the antipsychotic drug, which contains the active ingredient asenapine maleate. 

"Sigmapharm infringed one or more claims of the [Forest patents], in violation of plaintiffs' patent rights, by submitting to the FDA an ANDA that seeks approval to commercially...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS